EP1165752A4 - An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system - Google Patents

An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Info

Publication number
EP1165752A4
EP1165752A4 EP00975335A EP00975335A EP1165752A4 EP 1165752 A4 EP1165752 A4 EP 1165752A4 EP 00975335 A EP00975335 A EP 00975335A EP 00975335 A EP00975335 A EP 00975335A EP 1165752 A4 EP1165752 A4 EP 1165752A4
Authority
EP
European Patent Office
Prior art keywords
immune system
effector functions
recombinant molecule
engineered recombinant
cellular effector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00975335A
Other languages
German (de)
French (fr)
Other versions
EP1165752A2 (en
Inventor
William L Fodor
Maryellen Pizzolato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP1165752A2 publication Critical patent/EP1165752A2/en
Publication of EP1165752A4 publication Critical patent/EP1165752A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP00975335A 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system Withdrawn EP1165752A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16118699P 1999-10-22 1999-10-22
US161186P 1999-10-22
PCT/US2000/029151 WO2001030966A2 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Publications (2)

Publication Number Publication Date
EP1165752A2 EP1165752A2 (en) 2002-01-02
EP1165752A4 true EP1165752A4 (en) 2003-02-05

Family

ID=22580195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00975335A Withdrawn EP1165752A4 (en) 1999-10-22 2000-10-21 An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system

Country Status (4)

Country Link
EP (1) EP1165752A4 (en)
AU (1) AU1340101A (en)
CA (1) CA2361646A1 (en)
WO (1) WO2001030966A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006292827B2 (en) 2005-08-09 2013-02-14 Revivicor, Inc. Transgenic ungulates expressing CTLA4-IG and uses thereof
EP2464219B1 (en) 2009-08-14 2019-10-23 Revivicor, Inc. Multi-transgenic pigs for diabetes treatment
CN106432474A (en) 2010-03-12 2017-02-22 艾伯维生物医疗股份有限公司 CTLA4 proteins and their uses
ES2680636T3 (en) 2011-02-14 2018-09-10 Revivicor Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
JP2023551404A (en) 2020-11-20 2023-12-08 レビビコア， インコーポレイテッド Multiple transgenic pigs with growth hormone receptor knockout for cross-species transplantation
US20230255185A1 (en) 2021-09-20 2023-08-17 Revivicor, Inc. Multitransgenic pigs comprising ten genetic modifications for xenotransplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0682039A1 (en) * 1994-04-15 1995-11-15 Bristol-Myers Squibb Company CTLA4 molecules and IL4-binding molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0682039A1 (en) * 1994-04-15 1995-11-15 Bristol-Myers Squibb Company CTLA4 molecules and IL4-binding molecules and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRISTINA C ET AL: "Delayed rejection in a small animal model grafted with porcine cells expressing CTLA4-CD59 chimeric molecule to block pCD86.", XENOTRANSPLANTATION, vol. 8, no. Supplement 1, August 2001 (2001-08-01), VI Congress of the International Xenotransplantation Association;Chicago, Illinois, USA; September 29-October 03, 2001, pages 101, XP009002543, ISSN: 0908-665X *
FODOR WILLIAM L ET AL: "A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex.", JOURNAL OF IMMUNOLOGY, vol. 155, no. 9, 1995, pages 4135 - 4138, XP000608498, ISSN: 0022-1767 *
GEISSLER M ET AL: "Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 8, 1 May 1998 (1998-05-01), pages 857 - 867, XP004118495, ISSN: 0264-410X *
See also references of WO0130966A3 *
ZHAO X J ET AL: "Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 17, 24 April 1998 (1998-04-24), pages 10665 - 10671, XP002105089, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2001030966A3 (en) 2001-10-18
CA2361646A1 (en) 2001-05-03
AU1340101A (en) 2001-05-08
WO2001030966A2 (en) 2001-05-03
EP1165752A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
IL223047A (en) Antibody comprising an fc region and uses thereof
EP1218411A4 (en) Secreted proteins and uses thereof
IL158751A0 (en) Recombinant fusion proteins and the trimers thereof
IL147145A0 (en) ANTI-αvβ3 RECOMBINANT HUMAN ANTIBODIES AND NUCLEIC ACIDS ENCODING THE SAME
ZA200109428B (en) Recombinant bacterial phytases and uses thereof.
EP1076090A3 (en) ESTs and encoded human proteins
EP1076090A2 (en) ESTs and encoded human proteins
HK1043798A1 (en) Recombinant il-18 antibodies and their use
AU2002367859A8 (en) Polypeptide immobilization
AU2001294834A1 (en) Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002230953A1 (en) Recombinant phytases and uses thereof
EP1419175A4 (en) Replikin peptides and uses thereof
EP1414848A4 (en) Replikin peptides and uses thereof
GB9930519D0 (en) Uses of transport proteins
SI1462455T1 (en) Ser-Ser-Ser-Arg peptide and medicinal uses thereof
IL131212A0 (en) Recombinant virus and live-virus vaccines
EP1204424A4 (en) Recombinant rsv virus expression systems and vaccines
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
EP1165752A4 (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
HK1051544A1 (en) Novel hev antigenic peptide and methods
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
EP1246635A4 (en) O-superfamily conotoxin peptides
HUP0103162A3 (en) Ball-and-socket joint
EP1179000A4 (en) Secreted proteins and uses thereof
HUP0202270A3 (en) Antitumor antibodies, proteins, and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010802

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 15/00 B

Ipc: 7C 12N 5/00 A

Ipc: 7C 12N 15/63 B

Ipc: 7C 07K 1/00 B

Ipc: 7C 07K 17/00 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 12N 15/09 B

Ipc: 7C 07K 14/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021220

17Q First examination report despatched

Effective date: 20050503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050914